The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.

Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.

This week, Bioventus announced plans to sell its wound business; Pfizer and Thermo Fisher Scientific partnered to increase cancer screening access; and the FDA expanded the magnetic resonance imaging labeling for Abbott’s Eterna spinal cord stimulator.

The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.